Literature DB >> 27578474

Burden of COPD in patients treated in different care settings in the Netherlands.

Dionne E Smid1, Martijn A Spruit2, Sarah Houben-Wilke2, Jean W M Muris3, Gernot G U Rohde4, Emiel F M Wouters5, Frits M E Franssen5.   

Abstract

INTRODUCTION: Care for patients with chronic obstructive pulmonary disease (COPD) can be provided in primary, secondary or tertiary care. Whether and to what extent patients with COPD treated in various healthcare settings differ in disease burden and healthcare utilization remains unknown. Therefore, daily symptoms, functional mobility, mood status, health status and healthcare utilization were compared between COPD patients in various care settings, to explore possibilities for healthcare-optimization.
METHODS: Current data are part of the Chance study. Demographics, functional mobility (Care Dependency Scale (CDS); Timed-Up-and-Go (TUG) test), mood status (Hospital Anxiety and Depression scale (HADS)), health status (COPD Assessment test (CAT); Clinical COPD questionnaire (CCQ); COPD specific St. George Respiratory questionnaire (SGRQ-C)), received treatments and severity of physical and psychological symptoms were assessed in subjects with and without COPD.
RESULTS: 836 subjects (100 primary care patients, 100 secondary care patients, 518 tertiary care patients and 118 non-COPD subjects) were included. The burden of disease significantly increased from primary care to tertiary care. However, in all three healthcare settings a high percentage of patients with an impaired health status was observed (i.e. CAT ≥10 points, 68.0% vs. 91.0% vs. 94.5%, respectively). Furthermore, many patients treated in secondary care remain highly symptomatic despite treatment, while others with low burden of disease would allow for de-intensification of care.
CONCLUSION: This study revealed important shortcomings and challenges for the care of COPD patients in the Netherlands. It emphasizes the need for detailed patient characterization and more individualized treatment, independent of the healthcare setting.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COPD; Disease burden; Functional mobility; Health status; Healthcare settings; Mood status

Mesh:

Year:  2016        PMID: 27578474     DOI: 10.1016/j.rmed.2016.07.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

1.  Effect of internet-based self-management on pulmonary function rehabilitation and living quality in patients with chronic obstructive pulmonary disease.

Authors:  Qin Huang; Ping Lin; Jianhui Dang; Lizhen Fu; Lili Ding
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  The physical, mental, and social impact of COPD in a population-based sample: results from the Longitudinal Aging Study Amsterdam.

Authors:  Frits M E Franssen; Dionne E Smid; Dorly J H Deeg; Martijn Huisman; Jan Poppelaars; Emiel F M Wouters; Martijn A Spruit
Journal:  NPJ Prim Care Respir Med       Date:  2018-08-10       Impact factor: 2.871

Review 3.  Organizational aspects of pulmonary rehabilitation in chronic respiratory diseases.

Authors:  Martijn A Spruit; Emiel F M Wouters
Journal:  Respirology       Date:  2019-02-27       Impact factor: 6.424

4.  Treatable traits qualifying for nonpharmacological interventions in COPD patients upon first referral to a pulmonologist: the COPD sTRAITosphere.

Authors:  Alex J van 't Hul; Eleonore H Koolen; Jeanine C Antons; Marianne de Man; Remco S Djamin; Johannes C C M In 't Veen; Sami O Simons; Michel van den Heuvel; Bram van den Borst; Martijn A Spruit
Journal:  ERJ Open Res       Date:  2020-11-02

5.  Contribution of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation on CAT scores.

Authors:  Sarah Houben-Wilke; Daisy J A Janssen; Frits M E Franssen; Lowie E G W Vanfleteren; Emiel F M Wouters; Martijn A Spruit
Journal:  Health Qual Life Outcomes       Date:  2018-10-30       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.